» Articles » PMID: 25932044

Biology of Colorectal Cancer

Overview
Specialty Oncology
Date 2015 May 2
PMID 25932044
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is a serious health problem, a challenge for research, and a model for studying the molecular mechanisms involved in its development. According to its incidence, this pathology manifests itself in three forms: family, hereditary, and most commonly sporadic, apparently not associated with any hereditary or familial factor. For the types having inheritance patterns and a family predisposition, the tumours develop through defined stages ranging from adenomatous lesions to the manifestation of a malignant tumour. It has been established that environmental and hereditary factors contribute to the development of colorectal cancer, as indicated by the accumulation of mutations in oncogenes, genes which suppress and repair DNA, signaling the existence of various pathways through which the appearance of tumours may occur. In the case of the suppressive and mutating tracks, these are characterised by genetic disorders related to the phenotypical changes of the morphological progression sequence in the adenoma/carcinoma. Moreover, alternate pathways through mutation in BRAF and KRAS genes are associated with the progression of polyps to cancer. This review surveys the research done at the cellular and molecular level aimed at finding specific alternative therapeutic targets for fighting colorectal cancer.

Citing Articles

Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.

Taghizadeh-Teymorloei M, Jafarlou V, Matin S, Raeisi M, Roosta Y, Mansouri-Derakhshani S Clin Transl Oncol. 2025; .

PMID: 39969763 DOI: 10.1007/s12094-025-03863-8.


The HOX Gene Family's Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors.

Kopec K, Quaranto D, DeSouza N, Jarboe T, Islam H, Moscatello A Cancers (Basel). 2025; 17(2).

PMID: 39858044 PMC: 11763641. DOI: 10.3390/cancers17020262.


Barriers in early detection of colorectal cancer and exploring potential solutions.

Aleissa M, Drelichman E, Mittal V, Bhullar J World J Clin Oncol. 2024; 15(7):811-817.

PMID: 39071472 PMC: 11271734. DOI: 10.5306/wjco.v15.i7.811.


Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.

Zheng E, Wlodarczyk M, Wegiel A, Osielczak A, Mozdzan M, Biskup L Front Surg. 2024; 11:1398289.

PMID: 38948479 PMC: 11211389. DOI: 10.3389/fsurg.2024.1398289.


Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer.

Bakhsh T, Alhazmi S, Farsi A, Yusuf A, Alharthi A, Qahl S Sci Rep. 2024; 14(1):8902.

PMID: 38632250 PMC: 11024162. DOI: 10.1038/s41598-024-58536-3.


References
1.
Vale C, Tierney J, Fisher D, Adams R, Kaplan R, Maughan T . Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev. 2011; 38(6):618-25. DOI: 10.1016/j.ctrv.2011.11.002. View

2.
Oxentenko A, Smyrk T . Interval colon cancer in a Lynch syndrome patient under annual colonoscopic surveillance: a case for advanced imaging techniques?. BMC Gastroenterol. 2012; 12:50. PMC: 3493301. DOI: 10.1186/1471-230X-12-50. View

3.
Mecklin J . The implications of genetics in colorectal cancer. Ann Oncol. 2008; 19 Suppl 5:v87-90. DOI: 10.1093/annonc/mdn318. View

4.
Lee H, Wang N, Shao Y, Zheng J . Identification of tripeptides recognized by the PDZ domain of Dishevelled. Bioorg Med Chem. 2009; 17(4):1701-8. PMC: 2713185. DOI: 10.1016/j.bmc.2008.12.060. View

5.
Arvelo F, Cotte C, Sojo F . [Stem cells and cancer]. Invest Clin. 2015; 55(4):371-91. View